newsfilter
← Latest News
GlobeNewswire·

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative